Prevention Is Having a Moment and a Measurement Problem
The most expensive diseases in modern medicine are now being chased upstream by search engines, wearable sensors, and uneasy payment ...
Brain Health Is Becoming a Balance-Sheet Variable
Cognitive decline has quietly become one of the most expensive line items in modern healthcare, and the bill is only ...
Behavioral Health Is Now a Network Phenomenon
The center of gravity in behavioral health has shifted quietly but decisively — away from institutions and into networks. Search ...
Health Technology Assessment Is Moving Upstream
Health technology assessment is no longer confined to late-stage review after a product reaches market maturity. Payers, integrated delivery networks, ...
When Software Outruns Clinical Guidelines
Clinical guidelines and clinical software operate on fundamentally different update cycles. Guidelines are designed to change slowly. Software is designed ...
Why Interoperability Fails After Standards Succeed — Expanded Analysis
Healthcare interoperability is often described as a technical standards problem. The prevailing narrative suggests that once common data standards are ...
When Better Outcomes Disrupt Revenue Models — Expanded Analysis
Clinical improvement and financial improvement are often assumed to move in the same direction. In healthcare payment systems, that alignment ...
Cyber Risk Is Now a Core Procurement Metric — Expanded Analysis
Cybersecurity risk in healthcare has shifted from a technical concern to a core operational and procurement variable. Health system leaders ...
Clinical Workflow Is the Real Adoption Gatekeeper
Time is the dominant currency Clinician time scarcity shapes adoption more than feature richness. Seconds matter. Extra navigation steps accumulate ...
Data Governance Is Becoming the True AI Bottleneck
Data access is negotiated, not assumed Healthcare founders often treat data access as a partnership benefit. Institutions treat it as ...
Why Procurement Teams Now Study Failure Before Features
Resilience documentation is now standard Procurement packages increasingly require resilience artifacts: incident response plans, redundancy architecture diagrams, and dependency maps. ...
Reimbursement Friction Is Steering Innovation Pathways
Coding is the first gate, not the last Without a billing code, revenue attribution is difficult. Without revenue attribution, purchasing ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more